Recipharm adds capacity through ViroPharma contract

- Last updated on GMT

Recipharm adds capacity through ViroPharma contract
Swedish CDMO Recipharm will gain manufacturing capacity through its new production contract with ViroPharma.

Under the deal – which will see Recipharm make commercial supplies of the adrenal insufficiency drug Plenadren – ViroPharma will invest in new tablet manufacturing and active pharmaceutical ingredient (API) coating technology to be installed at the CDMO’s plant in Arsta, Stockholm

The agreement follows Recipharm’s completion of a scale-up contract​ with original Plenadren developer Sweden-based DuoCort, which was acquired by ViroPharma in November for an upfront payment of $33m (€25m).

Helene Fehrm, General Manager at Recipharm Stockholm told that: “we will be able to use the technology for other customers” although the US drugmaker “retains its status as a customer with the highest priority​.”

Related topics: Contract Manufacturing

Related news

Show more